After only a few years of successful clinical trials, recombinant human factor products become licensed and are available to hemophilia patients
The first recombinant factor VIII concentrate becomes commercially available. It is 1997 before a recombinant factor IX concentrate becomes commercially available. Recombinant products are not made from human plasma and so do not carry the same risk for transmitting diseases such as HIV/AIDS and hepatitis.
